SB202190 (FHPI)

Short Summary : P38 MAPK inhibitor

Category : MAPK Signaling|p38

Purity : 0.9935

CAS Number : 152121-30-7

Formula : C20H14N3OF

Molecular Weight : 331.34

SMILE : C1=CC(=O)C=CC1=C2NC(=C(N2)C3=CC=NC=C3)C4=CC=C(C=C4)F

Solubility : >16.6mg/mL in DMSO

Storage : Store at -20°C

Description : SB202190 (FHPI) is a potent p38 MAPK inhibitor that specifically inhibits p38 and p38 with IC50 values of 50 and 100 nM, respectively [1].SB202190 has been reported to potently enhance the growth of leukemia cell lines THP-1 and MV4-11. SB202190 activates the phosphorylation ERK and C-Raf. Studies have shown that the ED50 values of U0126 and FPT inhibitor II were significantly decreased in the presence of SB202190 [2].SB202190 triggers changes in cell cycle profiles both during HU treatment and caffeine-induced PCC (premature chromosome condensation) in plants. Moreover, SB202190 and caffeine decrease independently HU-induced histone H4 Lys5 acetylation [3].References:[1] Davies SP1, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.[2] Hirosawa M1, Nakahara M, Otosaka R, Imoto A, Okazaki T, Takahashi S. The p38 pathway inhibitor SB202190 activates MEK/MAPK to stimulate the growth of leukemia cells. Leuk Res. 2009 May;33(5):693-9.[3] Winnicki K1, Maszewski J. SB202190 affects cell response to hydroxyurea-induced genotoxic stress in root meristems of Vicia faba. Plant Physiol Biochem. 2012 Nov;60:129-36.

Download datasheet